The following six biosimilars were given a positive opinion at the June meeting: treatments for treatment of age-related macular degeneration and visual impairment: Mynzepli (aflibercept), and its ...

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...

Conshohocken, Pennsylvania Monday, June 23, 2025, 13:30 Hrs [IST] ...